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the time to neutrophil engraftment, the proportion of patients who develop acute graft versus host disease (GVHD), and survival at 100 days post transplant.
Study designs and other criteria for inclusion in the review
The literature search was conducted for studies that directly compared PB and BM technologies. There were no studies comparing either of these two with CB transplantation. Studies that reviewed the outcomes of CB transplantation were analysed separately. The studies included in the analysis were either randomised controlled trials or retrospective studies. Other criteria for inclusion in the review were not reported.
Sources searched to identify primary studies
Cancerlit was searched from 1996 to 1998. References with "bone marrow" and "stem cell transplant" in the titles were extracted. In addition, HealthSTAR was searched from 1990 to 1999. References with "bone marrow transplantation" or "haematopoietic stem cell transplantation" as subject words were extracted. The authors also searched manually for additional articles using the bibliographies of the retrieved articles.
Criteria used to ensure the validity of primary studies
Not reported.
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Seven primary studies were included in the analysis of PB and BM technologies. One retrospective study was included in the analysis of CB transplantation.
Methods of combining primary studies
Investigation of differences between primary studies
Differences between the primary studies, in terms of pretransplantation conditioning techniques, disease indications and the number of matching antigens, were investigated. The authors provided an explanation of differences between the individual studies.
Results of the review
The authors did not report the statistical analysis of primary outcomes. Donor safety was not significantly different between the BM and PB technologies. Donor safety for CB transplantation was negligible.
The activity of BM donors was more restricted than that of PB donors. BM donors had 3 days of restricted activity and 2 nights in hospital, while PB donors had 1 day of restricted activity and no hospitalisation.
The time to platelet engraftment was significantly more rapid for PB than BM technologies in five studies. The number of days to engraftment were 19, 20.5, 27, 15 and 17 with BM transplantation versus 14, 14, 22.5, 11 and 12,  respectively, with PB transplantation.
The time to platelet engraftment was 71 days for CB transplantation.
The time to neutrophil engraftment was significantly more rapid for PB than BM technologies in four studies. The number of days until engraftment for BM versus PB technologies were, respectively, 15 versus 11, 21.5 versus 16, 22 versus 19, and 16.5 versus 13.5. The time to neutrophil engraftment was significantly longer for PB than BM technologies in one study (10 versus 9 days).
The time to neutrophil engraftment was 28 days for CB transplantation.
The proportion of patients who developed acute GVHD was not significantly different between BM and PB technologies in any study. The data for CB transplantation were also inconclusive.
The 100-day survival was not significantly different between the BM and PB technologies.
Measure of benefits used in the economic analysis
No summary benefit measure was used in the economic evaluation. In effect, the study was a cost-consequences analysis.
Direct costs
Only direct costs of the health service were included. These were for donor maintenance and recruitment, collection, transport, processing, testing, confirmatory testing, harvesting and transplantation. It appears that the quantities have been estimated from actual data, using models drawing on Canadian experience. The authors made several assumptions to estimate the cost per recipient for each technology. The price year was 1999. The costs and the quantities were reported separately. Discounting was carried out because the costs were incurred during more than 2 years. A discount rate of 5% was used.
